Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio (CABA)
NASDAQ:CABA
Cabaletta Bio (CABA) Stock Price & Analysis
415 Followers
CABA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.02 - $26.35
Previous Close$12.39
Volume817.48K
Average Volume (3M)1.15M
Market Cap
$579.91M
Enterprise Value$343.68M
Total Cash (Recent Filing)$241.25M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)-7.5
Beta1.75
Next Earnings
May 09, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding48,241,615
10 Day Avg. Volume2,008,440
30 Day Avg. Volume1,153,416
Standard Deviation0.41
R-Squared0.11
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.10
Forecast
1Y Price Target
$32.00Price Target Upside158.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Cabaletta Bio News
Bulls Say, Bears Say
Bulls Say
Financial HealthCabaletta's robust financials, with a cash position that provides a runway into the first half of 2026, ensures the company can sustain its operations and advance its Investigational New Drug applications, signaling a stable investment.
Product PipelineCabaletta's lead candidate, CABA-201, shows promise with an encouraging safety profile as no severe side effects were reported in early trials, which may enhance investor confidence in the company's pipeline.
Regulatory MilestoneThe FDA's rare pediatric disease designation for CABA-201 underscores its potential to meet significant unmet medical needs, potentially accelerating its path to market and benefiting stock valuation.
Bears Say
Clinical Trial ConcernsThe RA study has revealed concerns about the longevity of remission and the necessity for continuous maintenance therapy.
CompetitionCABA shares have declined as the market reacts to increasing competition in the autoimmune cell therapy sector.
Financial PerformanceThe company's operating loss has expanded significantly, surpassing analyst estimates and signaling potential financial instability.
---
Ownership Overview
9.02% Insiders
19.66% Mutual Funds
22.72% Other Institutional Investors
48.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $9.02 and its highest was $26.35 in the past 12 months.
What is Cabaletta Bio’s market cap?
Currently, no data Available
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is May 09, 2024 which is in 4 days.
How were Cabaletta Bio’s earnings last quarter?
Cabaletta Bio released its earnings results on Mar 21, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.393 by -$0.067.
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -$0.48.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 46,804,820 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Cabaletta Bio reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.393. Following the earnings report the stock price went down -3.201%.
Which hedge fund is a major shareholder of Cabaletta Bio?
Among the largest hedge funds holding Cabaletta Bio’s share is Deerfield Management Company, LP. It holds Cabaletta Bio’s shares valued at 46M.
---
Cabaletta Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.00 (158.27% Upside)
$32.00 (158.27% Upside)
Blogger Sentiment
Bullish
CABA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 587.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.22%
12-Months-Change
Fundamentals
Return on Equity
-39.72%
Trailing 12-Months
Asset Growth
116.85%
Trailing 12-Months
Company Description
Cabaletta Bio
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
---
CABA Stock 12 Months Forecast
Average Price Target
$32.00
▲(158.27% Upside)
Technical Analysis
MacroGenics
―
Corvus Pharmaceuticals
―
Crispr Therapeutics AG
―
Adverum Biotechnologies
―
Best Analysts Covering CABA
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+205.38%
assigned a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +205.38% per trade.
---